Correction to: LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma

Affiliations

Fei Teng: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Ju-Xiang Zhang: Shanghai Med-X Engineering Center for Medical Equipment and Technology, School of Biomedical Engineering, Shanghai Jiao Tong University
Qi-Meng Chang: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Xu-Bo Wu: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Wei-Guo Tang: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Jian-Fa Wang: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Jin-Feng Feng: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Zi-Ping Zhang: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University
Zhi-Qiu Hu: Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University

Abstract

An amendment to this paper has been published and can be accessed via the original article.

ISSN: 1756-9966 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jeccr.biomedcentral.com/